Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)

Dittner-Moormann, Sabine; Reschke, Madlen; Abbink, Floor; Aerts, Isabelle; ATALAY, HATİCE; Fedorovna Bobrova, Nadezhda; Biewald, Eva; Brecht, Ines; Caspi, Shani; Cassoux, Nathalie; Castela, Guilherme; Diarra, Yelena; Duncan, Catriona; Ebinger, Martin; Garcia Aldana, David; Hadjistilianou, Doris; Kepak, Tomas; Klett, Artur; KIRATLI, HAYYAM; Maka, Erika; Opocher, Enrico; Pawinska-Wasikowska, Katarzyna; Rascon, Jelena; Russo, Ida; Rutynowska-Pronicka, Olga; Sabado alvarez, Constantino; Pacheco, Sonsoles; Svojgr, Karel; Timmermann, Beate; Vishnevskia-Dai, Vicktoria; Eggert, Angelika; Ritter-Sovinz, Petra; Bechrakis, Nikolaos; Jenkinson, Helen; Moll, Annette; Munier, Francis; Popovic, Maja; Chantada, Guillermo; Doz, Francois; Ketteler, Petra

doi:10.1002/pbc.28963

Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)

Copy For Citation

Dittner-Moormann S., Reschke M., Abbink F. C. H., Aerts I., ATALAY H. T., Fedorovna Bobrova N., ...More

PEDIATRIC BLOOD & CANCER, vol.68, no.6, 2021 (SCI-Expanded)

Publication Type: Article / Article
Volume: 68 Issue: 6
Publication Date: 2021
Doi Number: 10.1002/pbc.28963
Journal Name: PEDIATRIC BLOOD & CANCER
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
Keywords: biomarker, chemotherapy, childhood cancer, metastasis, radiotherapy, RB1 gene
Hacettepe University Affiliated: Yes

Abstract

Introduction Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment.